Which neurotransmitter's levels are primarily affected by SSRIs?

Selective serotonin reuptake inhibitors, commonly known as SSRIs, primarily target serotonin levels in the brain. These medications work by inhibiting the reuptake of serotonin, which is a neurotransmitter that plays a crucial role in mood regulation, anxiety, and overall emotional well-being. By blocking the reabsorption (reuptake) of serotonin into the presynaptic neuron, SSRIs increase the availability of serotonin in the synaptic cleft, leading to enhanced serotonin signaling. This increased availability is believed to contribute to the therapeutic effects of SSRIs in treating depression and anxiety disorders.

Serotonin's importance in mood disorders is well-established, which is why SSRIs are commonly prescribed for conditions such as major depressive disorder and anxiety disorders. Other neurotransmitters, while important in their own right, are not the primary target of SSRIs, which is why they do not play a significant role in the mechanism of action of these medications. Understanding this specific action helps elucidate the direct impact SSRIs have on serotonin levels and their role in the management of affective disorders.